MedTrace Logo

Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa

NCT05786287 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2026-02-25

No results posted yet for this study

Summary

The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.

Conditions

Interventions

BIOLOGICAL

Conditioned Medium (CM)

Conditioned Medium (CM) injected by peribulbar

BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cell (UC-MSC)

Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar

Sponsors & Collaborators

  • PT. Prodia Stem Cell Indonesia

    lead INDUSTRY

Principal Investigators

  • dr. Muhammad B Sasongko, Sp.M, M.Epid, PhD · Gadjah Mada University, Faculty of Medicine

  • dr Cosmos O Mangunsong, Sp.M · Jakarta Eye Center

  • dr. Rifa Widyaningrum, M.Sc, PhD · Sardjito Hospital

  • Rima Haifa, S.Si · Prodia StemCell Indonesia

  • Marsya N Kirana, S.T., M.Sc · Prodia StemCell Indonesia

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-07-31
Completion
2027-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05786287 on ClinicalTrials.gov